Dog Bite Vaccine

Manufactured by AIM Honor, our dog bite vaccine utilizes local aG virus strains and advanced serum-free culture technology. It boasts a 100% antibody seroconversion rate within 14 days, is administered via intramuscular injection only, and contains no preservatives or bovine serum. With superior safety and immunogenicity, stable supply, and support for bulk purchasing, it is a core choice for rabies prevention and control after dog exposure!

Product Features

This Dog Bite Vaccine is a targeted rabies preventive product for post-exposure scenarios caused by dog-related injuries, with National Drug Approval Number S20073014 for the conventional version and the serum-free version entering the marketing approval stage.

The conventional vaccine is prepared by inoculating rabies fixed virus aG strain on Vero cells, while the serum-free vaccine innovatively adopts serum-free Vero cell culture technology, eliminating the addition of bovine serum throughout the entire production process (including cell revival, expansion, and virus cultivation), which fundamentally avoids the risks of viral contamination, batch-to-batch quality variability, and allergic reactions caused by bovine serum.

In line with WHO rabies exposure classification standards, the vaccine is suitable for Category II (non-bleeding bites/scratches) and Category III (bleeding bites/scratches, mucosal contact) dog-related exposures. After intramuscular injection (1.0ml per dose, administered on days 0, 3, 7, 14, and 28), it can rapidly stimulate the body to produce high-titer neutralizing antibodies, with 100% seroconversion rate at 14 days, far exceeding the WHO effective protection standard of 0.5 IU/ml. For Category III exposures, it can be used in combination with rabies immunoglobulin (20IU/kg) to form a comprehensive protective barrier.

Product Specification

Core Advantages

Dual-category to meet needs: Conventional version has mature technology and high cost-effectiveness, with cumulative supply exceeding 100 million doses; serum-free version is an upgraded product, avoiding bovine serum-related risks, with adverse reactions mainly mild Grade 1-2, no Grade 4 or above severe reactions, and better safety.

High-efficiency immune guarantee: 100% antibody seroconversion rate in 14 days; antibody GMC of serum-free version in both 5-dose and 4-dose groups far exceeds protection standards, and immune persistence can reach more than 3 months, providing long-term protection for dog bite-exposed populations.

Strong compliance: Conventional version Dog Bite Vaccine complies with national pharmacopoeia standards; serum-free version has completed Phase III clinical trials and CDE has accepted the marketing application; both support sequential vaccination with other brands of vaccines, suitable for global dog bite-related rabies prevention and control scenarios.

Application Scenarios

Medical institutions: Community hospitals and emergency centers for emergency post-exposure vaccination after dog bites; can be combined with rabies immunoglobulin to provide comprehensive protection for Category III exposure patients.

Pet-related scenarios: Pet hospitals and pet markets provide post-exposure prevention for dog breeders and pet practitioners, reducing occupational exposure risks.

Public health prevention and control: Suitable for bulk procurement in high-incidence areas of dog-transmitted rabies such as Asia and Africa, supporting large-scale immunization work.